Walleye Capital LLC Has $2.57 Million Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Walleye Capital LLC raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 107.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 580,097 shares of the biotechnology company’s stock after purchasing an additional 299,798 shares during the quarter. Walleye Capital LLC’s holdings in Ironwood Pharmaceuticals were worth $2,570,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Pacer Advisors Inc. lifted its position in Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after buying an additional 450,949 shares in the last quarter. State Street Corp lifted its holdings in Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after purchasing an additional 677,024 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 102.7% in the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company’s stock worth $1,333,000 after buying an additional 164,006 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Ironwood Pharmaceuticals by 4.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after acquiring an additional 78,969 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at approximately $53,000.

Ironwood Pharmaceuticals Trading Down 3.3 %

Ironwood Pharmaceuticals stock opened at $0.73 on Friday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.59 and a 1 year high of $8.45. The company’s 50-day moving average is $1.44 and its two-hundred day moving average is $3.02. The company has a market cap of $117.31 million, a PE ratio of -24.17 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). The business had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IRWD. Wells Fargo & Company reissued an “equal weight” rating and issued a $1.00 price target (down from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday. Citizens Jmp cut Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 14th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Jefferies Financial Group reissued a “hold” rating and issued a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday. Finally, StockNews.com lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.78.

Insider Activity at Ironwood Pharmaceuticals

In related news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.